Clinical trials: Metabolism of Clopidogrel
Primary Hypercholesterolemia, Mixed Hyperlipidemia
A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary…
- Trial name
- NCT01012219
- Testing
- niacin (+) laropiprant, Comparator: aspirin, Comparator: clopidogrel
- Volunteers
- 36 people
- Sponsor
- Merck Sharp & Dohme LLC
Type-2 Diabetes Mellitus, Coronary Artery Disease
Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients
The purpose of this study is to determine whether treatment with ticagrelor + aspirin is more effective than treatment with clopidogrel + aspirin in patients with type-2 diabetes.
- Trial name
- NCT01823510
- Testing
- Ticagrelor + Aspirin, Clopidogrel + Aspirin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Juan J Badimon
Diabetes Mellitus, Type 2
PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor
The purpose of this study is to determine whether Ticagrelor has a protective effect on microcirculation during percutaneous coronary interventions in patients with Diabetes mellitus type II or in a pre-diabetic status.
- Trial name
- PREDICT (NCT02698618)
- Testing
- Diagnostic, Randomization, PCI
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundacion Investigacion Interhospitalaria Cardiovascular
Metabolism of Clopidogrel
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug.
- Trial name
- PGXB2B (NCT01341600)
- Testing
- Clopidogrel, Omeprazole/Clopidogrel
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes Mellitus, Coronary Artery Disease
Platelet-dependent Thrombosis: a Placebo-controlled Trial of Antiplatelet Therapy (Clopidogrel)
Patients with diabetes are more likely to develop furring of their coronary arteries and present with angina and heart attacks. Furthermore, after such an event, they have poorer outcomes (higher rates of death) and survivors are…
- Trial name
- NCT00728156
- Testing
- clopidogrel
- Where
- 2 sites in United Kingdom
- Volunteers
- 90 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Coronary Artery Disease, Diabetes Mellitus, Type 2
Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention
This will be a single-center, randomized, open-label, active-controlled, parallel-group study to investigate the platelet inhibition of Ticagrelor versus Clopidogrel with acetylsalicylic acid (ASA) as background therapy in…
- Trial name
- PLATIDE-PCI (NCT02748330)
- Testing
- Ticagrelor, Clopidogrel, Aspirin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS
Clopidogrel, in addition to aspirin, is the cornerstone of therapy in patients suffering from Acute coronary syndrome. However, the platelet inhibitory response to clopidogrel varies substantially among individuals.
- Trial name
- GI-CT (NCT02048228)
- Testing
- genotyping guided therapy Ticagrelor, Clopidogrel, standard therapy clopidogrel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Diabetes Mellitus, Coronary Artery Disease
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
This trial is designed as a phase 2 randomized, double-blind double dummy, active comparator controlled, two-period two-arm crossover study to enroll 40 patients across multiple centers.
- Trial name
- OPTIMUS-3 (NCT00642174)
- Testing
- prasugrel, Clopidogrel
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- Eli Lilly and Company
Ischemic Stroke, Peripheral Artery Disease
Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?
Investigation of the clinical efficacy and safety of dual antiplatelet therapy with clopidogrel and cilostazol versus clopidogrel alone in preventing ischemic vascular events in patients with type 2 diabetes and symptomatic…
- Conditions
- Ischemic Stroke, Peripheral Artery Disease, Diabetes Mellitus, Type 2
- Trial name
- DORIC (NCT02983214)
- Testing
- Clopidogrel, Cilostazol
- Where
- Greece
- Volunteers
- 826 people
- Sponsor
- University of Ioannina
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Coronary Artery Disease, Diabetes Mellitus
Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk
Ramadan fasting (RF) has been shown to be associated with vascular and metabolic disorders including glycemic control and lipid profile. It may also alter pharmacologic properties of some medications.
- Trial name
- RFeCloR (NCT02624583)
- Where
- 2 sites in Tunisia
- Volunteers
- 98 people
- Sponsor
- University of Monastir
Healthy Volunteers
An Interaction Study to Evaluate the Effect of Esomeprazole/Acetylsalicylic Acid on the Metabolism and Effect of Clopidogrel
The primary purpose of this study is to assess whether esomeprazole 20 mg/Acetyl Salicylic Acid (ASA) 81 mg affect the metabolism of clopidogrel.
- Trial name
- NCT01210339
- Testing
- Clopidogrel, Esomeprazole/ASA
- Where
- Sweden
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Diabetes Mellitus Type II, Acute Coronary Syndrome
VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel
The purpose of this study is to determine if, in type 2 diabetic patients undergoing treatment with PCI and a stent, who fail to respond to normal doses of clopidogrel, a loading dose of 60 mg of prasugrel followed by 10 mg once…
- Trial name
- VERDI (NCT01684813)
- Testing
- Prasugrel., Clopidogrel
- Where
- Spain
- Volunteers
- 65 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Coronary Artery Disease, Diabetes Mellitus
Clopidogrel Versus Ticagrelor in Type-2 Diabetes
CLOTILDIA is a single-center, prospective, randomized, open label, cross-over study evaluating the effects of ticagrelor versus high-dose clopidogrel on endothelial function and platelet reactivity in patients with type-2…
- Trial name
- NCT02742987
- Testing
- Ticagrelor, Clopidogrel, Standard medical therapy
- Volunteers
- 42 people
- Sponsor
- Campus Bio-Medico University
Diabetes, Clopidogrel Resistance
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD
Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes.
- Conditions
- Diabetes, Clopidogrel Resistance, Amyloid, Insulin Resistance
- Trial name
- NCT04027712
- Where
- Greece
- Volunteers
- 120 people
- Sponsor
- University of Athens
Myocardial Ischemia, CLOPIDOGREL, POOR METABOLISM of (Disorder)
Genotyping Influences Outcome of Coronary Artery Stenting
This study evaluated epidemiology and clinical outcome of clopidogrel related various genotyping in Korean patients who had undergone percutaneous coronary intervention as a all comer registry form.
- Trial name
- GENIUS (NCT02707445)
- Testing
- Clopidogrel
- Volunteers
- 5,000 people
- Sponsor
- Korea University Anam Hospital
Diabetes Mellitus, Coronary Disease
Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel
In recent years numerous studies have shown that the response of patients to the anti-platelet drug clopidogrel is widely variable.
- Trial name
- MATTIS-D (NCT01643031)
- Testing
- Ticagrelor, Continued clopidogrel
- Where
- Israel
- Volunteers
- 500 people
- Sponsor
- Rabin Medical Center
Cerebral Infarction, Clopidogrel,Poor Metabolism of (Disorder)
The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction
The investigators team had found that the presence of dynamic changes of Clopidogrel resistance are not associated with genetic factors.
- Trial name
- NCT02411903
- Testing
- atorvastatin and clopidogrel, rosuvastatin and clopidogrel
- Volunteers
- 160 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
Multiple Electrode Aggregometry & Clopidogrel Resistance
Antiplatelet therapy with aspirin-clopidogrel reduces the risk of cardiovascular episodes after percutaneous coronary intervention (PCI) in patients with acute coronary syndromes.
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD), Myocardial Infraction
- Trial name
- NCT01991093
- Where
- 3 sites in Greece
- Volunteers
- 280 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Peripheral Artery Disease, Clopidogrel, Poor Metabolism of
The Value of Screening for HPR in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
This is a randomized controlled trial designed to evaluate the role of screening for and intervening on patients with high on treatment platelet reactivity undergoing lower extremity arterial endovascular interventions.
- Conditions
- Peripheral Artery Disease, Clopidogrel, Poor Metabolism of, Peripheral Vascular Disease, Artery Disease
- Trial name
- NCT04007055
- Testing
- Point of care screening for HPR, Ticagrelor 90mg
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Marissa Jarosinski